Crinetics Pharmaceuticals Announces May 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Crinetics granted non-qualified stock option awards to purchase an aggregate of 152,475 shares of its common stock and an aggregate of 101,800 restricted stock unit awards to 35 new non-executive employees.

Crinetics Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update


Crinetics Pharmaceuticals reports first quarter 2025 financial results and provided a business update on May 8, 2025 at 4:30PM ET.

Crinetics Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025


Crinetics Pharmaceuticals to report first quarter 2025 financial results and provide a business update on May 8, 2025 after market close.

Crinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Crinetics granted non-qualified stock option awards to purchase an aggregate of 124,950 shares of its common stock and an aggregate of 84,725 restricted stock unit awards to 26 new non-executive employees.

Crinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) and Orphan Drug Designation (ODD) for Paltusotine in Acromegaly


Crinetics announces European Medicines Agency Validation of Marketing Authorization Application and Orphan Drug Designation for paltusotine in acromegaly.